Retatrutide

Retatrutide, designated LY3437943 by its developer Eli Lilly, is a 39-amino-acid synthetic peptide representing the first clinical-stage triple hormone receptor agonist designed specifically for metabolic disease. It targets three receptors in the incretin and glucagon system — GLP-1, GIP, and glucagon receptors — simultaneously. This design distinguishes retatrutide from earlier approved agents like semaglutide (GLP-1 only) and tirzepatide (GLP-1 and GIP), and from any compound previously tested at this scale in humans.

The rationale for combining all three receptor targets emerged from decades of metabolic research showing that each receptor contributes differently to energy balance. GLP-1 receptor agonism suppresses appetite and slows gastric emptying. GIP receptor agonism appears to amplify insulin release and may support fat metabolism. Glucagon receptor agonism increases energy expenditure and promotes fat breakdown in the liver. On its own, glucagon raises blood sugar — a historical barrier to its therapeutic use — but when paired with GLP-1 and GIP activity, this effect is counteracted by increased insulin secretion, allowing the energy-expenditure benefits to emerge without dangerous hyperglycemia.

Researchers study retatrutide because its Phase 2 results, published in the New England Journal of Medicine in 2023, produced weight loss figures that exceeded anything previously reported in a pharmacological trial of this duration. Participants receiving the highest tested dose lost an average of 24.2% of their body weight over 48 weeks — numbers approaching the results seen with bariatric surgery. This led to significant scientific and commercial interest in the compound.

Beyond weight management, Phase 2 trial data published in Nature Medicine in 2024 showed meaningful reductions in liver fat content in patients with metabolic dysfunction-associated steatotic liver disease (MASLD), a condition affecting an estimated 25% of the global population with few approved pharmacological treatments. The Lancet published a parallel Phase 2 trial in August 2023 examining retatrutide's effects in adults with type 2 diabetes, finding substantial reductions in glycated hemoglobin (HbA1c) alongside body weight reduction.

Retatrutide is administered as a once-weekly subcutaneous injection, consistent with other long-acting incretin therapies. Eli Lilly has progressed the compound into Phase 3 trials across obesity, diabetes, and liver disease indications. As of mid-2025, no regulatory approval has been granted anywhere in the world, and it remains an investigational compound.

Retatrutide is a balanced triple agonist at the GLP-1 receptor (GLP-1R), GIP receptor (GIPR), and glucagon receptor (GCGR). Each receptor is a G protein-coupled receptor (GPCR), and the compound was engineered with a fatty acid side chain that extends its plasma half-life, enabling once-weekly subcutaneous dosing. Its 39-amino-acid backbone was optimized to achieve balanced potency across all three receptor targets rather than selective activation of any single one.

At the GLP-1 receptor, retatrutide mimics native GLP-1, a gut-derived incretin hormone. GLP-1R activation in pancreatic beta cells stimulates glucose-dependent insulin secretion via cyclic AMP (cAMP) signaling, reducing postprandial blood glucose. In the hypothalamus and brainstem, GLP-1R activation suppresses appetite signals, reduces food intake, and slows gastric emptying, which together produce a sustained caloric deficit.

At the GIP receptor, retatrutide activates pathways that further amplify glucose-stimulated insulin release. GIP receptor agonism also appears to reduce the nausea that GLP-1R agonism alone can produce, improving tolerability. Some preclinical evidence suggests GIPR activation in adipose tissue may also modulate fat storage and lipolysis, though the precise contribution in humans remains under investigation.

The glucagon receptor component is pharmacologically distinct and historically complicated. Native glucagon raises blood glucose by stimulating hepatic glycogenolysis and gluconeogenesis — properties that made glucagon receptor agonism seem counterproductive in metabolic disease. However, when glucagon receptor activation is paired with GLP-1R and GIPR agonism, the insulin-raising and glucagon-counteracting effects of the latter two pathways prevent net hyperglycemia. What remains are the metabolic benefits of glucagon receptor activation: increased hepatic fat oxidation, elevated energy expenditure through thermogenesis, and promotion of lipolysis. In patients with metabolic dysfunction-associated steatotic liver disease (MASLD), this hepatic fat reduction mechanism is thought to be particularly important.

The net effect of triple receptor co-activation is a reduction in caloric intake, an increase in caloric expenditure, improved glycemic control, and reduction of ectopic fat deposition — particularly in the liver. Researchers believe this multi-pathway mechanism explains why retatrutide's weight loss data exceed those of dual or single agonists tested at comparable durations.

The most influential study of retatrutide to date is the Phase 2 trial published in the New England Journal of Medicine in August 2023 (PMID 37366315). This randomized, double-blind, placebo-controlled trial enrolled 338 adults with obesity or overweight with at least one weight-related comorbidity. Participants received once-weekly subcutaneous injections of retatrutide at doses of 1 mg, 4 mg, 8 mg, or 12 mg, or placebo, over 48 weeks. The highest-dose group (12 mg) achieved a mean weight reduction of 24.2% from baseline, compared with 2.1% in the placebo group. The 8 mg group lost an average of 22.8%. These figures are the largest weight reductions reported in any pharmacological trial of this duration, exceeding results from approved agents including semaglutide 2.4 mg (approximately 15% in STEP 1) and tirzepatide 15 mg (approximately 21% in SURMOUNT-1).

A parallel Phase 2 trial in adults with type 2 diabetes, published in the Lancet in August 2023 (PMID 37385280), was a randomized, double-blind, placebo- and active-controlled study. Participants received retatrutide at 4 mg, 8 mg, or 12 mg weekly, or dulaglutide 1.5 mg as an active comparator, for 36 weeks. Retatrutide at 12 mg reduced HbA1c by approximately 2.2 percentage points from baseline — superior to dulaglutide — and produced weight loss of roughly 16.9% in that dose group.

A Phase 2a trial for MASLD published in Nature Medicine in July 2024 (PMID 38858523) enrolled adults with biopsy-confirmed metabolic steatohepatitis. After 24 weeks of retatrutide treatment, researchers observed substantial reductions in liver fat content as measured by MRI-derived proton density fat fraction, with significant proportions of participants achieving a 30% or greater reduction from baseline. Histological improvements in fibrosis were also observed in a subset of participants, though larger and longer trials are needed to confirm this finding.

Systematic reviews published in Pharmacological Reviews (2025, PMID 39952695) and Biomolecules (2025, PMID 40563436) have positioned retatrutide as among the most promising obesity pharmacotherapies in the pipeline, noting its superior weight loss data relative to currently approved agents. A 2024 review in the European Journal of Pharmacology (PMID 39515565) summarized the compound's mechanism and clinical data, describing the glucagon receptor component as a key differentiator. A 2024 Diabetes Care study (PMID 38687506) raised the question of whether resistance exercise alongside incretin-based therapies like retatrutide could help preserve lean muscle mass, given that a proportion of weight lost with these agents is lean tissue — a limitation that applies to retatrutide as well. All major efficacy data published to date come from Phase 2 human trials. Phase 3 data are not yet available.

Published Phase 2 trials tested once-weekly subcutaneous doses of 1 mg, 4 mg, 8 mg, and 12 mg of retatrutide in adults with obesity (NEJM, 2023, PMID 37366315), and doses of 4 mg, 8 mg, and 12 mg in adults with type 2 diabetes (Lancet, 2023, PMID 37385280). In both trials, doses were titrated upward from lower starting doses over the initial weeks to improve tolerability. The MASLD Phase 2a trial (Nat Med, 2024, PMID 38858523) used a similar dosing range. All doses were administered as once-weekly subcutaneous injections in a controlled clinical research setting. Phase 3 dose selection has not been formally published as of mid-2025.

The safety profile of retatrutide in published Phase 2 trials is broadly consistent with other GLP-1 receptor agonist-based therapies, though its glucagon receptor activity adds a dimension not seen with approved incretin agents. Data from the NEJM 2023 Phase 2 obesity trial (PMID 37366315) showed that nausea, vomiting, diarrhea, and constipation were the most frequently reported adverse events, particularly during dose escalation periods. Most gastrointestinal events were described as mild to moderate in severity. The rate of treatment discontinuation due to adverse events was higher in the highest-dose groups compared with placebo.

Heart rate elevation is a known pharmacological effect of glucagon receptor agonism. The NEJM trial reported small mean increases in resting heart rate in retatrutide-treated participants, a finding also observed with other GLP-1R agonists including semaglutide. This warrants monitoring in individuals with underlying cardiovascular conditions, and its long-term significance at higher doses is not yet established.

Bile composition changes and gallbladder-related adverse events, including cholelithiasis (gallstones), have been associated with rapid weight loss and with GLP-1R agonist therapy in general. The Phase 2 trials reported gallbladder adverse events at rates numerically higher in treated groups than placebo, though the absolute numbers were small. The MASLD trial (Nat Med, 2024, PMID 38858523) did not reveal new safety signals specific to the liver disease population.

A concern specific to triple agonism is the theoretical risk that glucagon receptor activation could worsen glycemic control in individuals with severely impaired beta cell function, though trial data in type 2 diabetes participants (Lancet, 2023, PMID 37385280) showed net glycemic improvement across all doses, suggesting the GLP-1 and GIP components adequately offset this risk in the populations studied.

Loss of lean muscle mass alongside fat loss has been observed with incretin-based therapies and was discussed in the context of retatrutide in a 2024 Diabetes Care analysis (PMID 38687506). The proportion of weight lost as lean tissue in high-dose groups is not trivial, and strategies to mitigate this — such as resistance training — remain under investigation. Long-term safety data from Phase 3 trials, including cardiovascular outcomes, bone density, lean mass preservation, and thyroid effects, are not yet available.

Retatrutide is currently in Phase 3 clinical development, sponsored by Eli Lilly and Company. Phase 2 trials in obesity, type 2 diabetes, and metabolic dysfunction-associated steatotic liver disease have been completed and published in high-impact journals including the New England Journal of Medicine, the Lancet, and Nature Medicine. No regulatory approval has been granted by the FDA, EMA, or any other major regulatory body as of mid-2025.

Key ongoing research questions include long-term cardiovascular safety, the optimal dose for specific patient populations, the clinical significance of glucagon receptor-mediated heart rate increases, and strategies to preserve lean muscle mass during weight loss. The MASLD indication is of particular interest given the lack of widely approved pharmacological treatments for that condition. Systematic reviews published in 2025 in Pharmacological Reviews and Biomolecules identify retatrutide as among the most promising agents in the obesity pharmacotherapy pipeline. Phase 3 results are anticipated in the next several years.